AXGN:NASDAQ
AxoGen, Inc Common Stock
55,93 US$
0,00%
(0,00) 1K
55,70 US$
arrow_downward
-0,41% (-0,23)todayBirjadan oldin
Savdolar yopilgan: 13-noy, 16:00:01 (GMT-5) · USD
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoAXGN tikeri uchun statistika yaratilmoqda...
Bozor kapitali
3,34 mlrd
Oʻrtacha hajm
1,92 mln
Hajmi
1,68 ming
52 haftalik eng yuqori
59,72 US$
52 haftalik eng past
23,00 US$
Aksiya boʻyicha daromad
-0,68 US$
Beta
1,21
Muomaladagi aksiyalar
59,73 mln
Xodimlar soni
622
Bozor kapitali
3,34 mlrd
Oʻrtacha hajm
1,92 mln
Hajmi
1,68 ming
52 haftalik eng yuqori
59,72 US$
52 haftalik eng past
23,00 US$
Aksiya boʻyicha daromad
-0,68 US$
Beta
1,21
Muomaladagi aksiyalar
59,73 mln
Xodimlar soni
622
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
ChartMill
·
35 daqiqa oldin
S&P 500 Premarket Losers on Nov. 16, 2026: COIN, LITE, COHR
Kitco
·
1 soat oldin
S&P 500, Nasdaq futures fall ahead of Nvidia earnings, Anthropic IPO
Investing.com
·
2 soat oldin
Barclays joins Morgan Stanley in seeing S&P 500 at 8,700 by end-2027
FXEmpire
·
56 daqiqa oldin
Why The S&P 500 Could Fall 63% – And Still Only Be Fairly Valued
Profil
Axogen is a developer of surgical solutions, including human tissue grafts, based in Tampa, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology Avance to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available nerve allograft approved by the Food and Drug Administration for clinical use. Wikipedia
AxoGen, Inc Common Stock haqida
CEO-
Xodimlar soni622
Asos solingan2002
Bosh ofislarAlachua, Florida, Amerika Qo‘shma Shtatlari
SektorHealth Care
Soha-
Veb-saytaxogeninc.com